Treatment of Melanoma In Situ on Sun-Damaged Skin With Topical 5% Imiquimod Cream Complicated by the Development of Invasive Disease

Fisher, Galen H.; Lang, P.G.

doi:10.1001/archderm.139.7.945

Cited by 83 publications

(82 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial 5,6 was a vehicle-controlled randomized controlled trial (RCT) that studied whether topical tretinoin, 0.1%, cream applied to the face and ears could prevent nonmelanoma skin cancer. As reported in an abstract published in 2005, 6 the study observed 1131 subjects for at least 2 years.…”

Section: Comments and Opinionsmentioning

confidence: 99%

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

L entigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma. 1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm. 2 A margincontrolled excision using "slow Mohs" (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%. 3Methods. Thirty-two patients with 34 histologically confirmed facial LM lesions were enrolled in an open-label trial of imiquimod, 5%, cream (Aldara; 3M Pharma, Rueschlikon, Switzerland). No patient had been treated

show abstract

Section: Comments and Opinionsmentioning

confidence: 99%

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…57 Four separate case studies observed clearance of LM after application of imiquimod cream. [58][59][60][61] In 2003, Naylor et al 62 conducted a trial with 30 subjects who applied imiquimod daily for 3 months. At the end of the 3 months, 28 of the subjects had completed the treatment phase and 26 (93%) were complete responders.…”

Section: Lentigo Maligna (Lm)mentioning

confidence: 99%

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

“…56 Clearance rates with imiquimod vary widely, with some MIS lesions failing to respond at all and others clearing 100% with no evidence of recurrence. [57][58][59][60][61][62][63][64][65][66][67][68][69] Treatment regimens also varied widely, with some using the medication several days a week and others using it only once weekly. Similarly, the treatment period ranged from 4 to 36 weeks.…”

Section: Staged Excision Key Pointsmentioning

confidence: 99%

“…In some cases, tumor recurred as LM melanoma, highlighting the risk that imiquimod may not treat deeper components of the tumor. 66,70 A rigorous protocol using daily applications of imiquimod for 12 weeks has been proposed for the treatment of MIS. There must be clinical erythema during a minimum of 10 of the 12 weeks.…”

Section: Staged Excision Key Pointsmentioning

confidence: 99%